nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.378	1	CiPCiCtD
Afatinib—Vandetanib—Erlotinib—pancreatic cancer	0.138	0.635	CrCrCtD
Afatinib—EGFR—pancreatic cancer	0.107	1	CbGaD
Afatinib—Gefitinib—Erlotinib—pancreatic cancer	0.0792	0.365	CrCrCtD
Afatinib—DYRK1A—Sunitinib—pancreatic cancer	0.0286	0.13	CbGbCtD
Afatinib—PHKG2—Sunitinib—pancreatic cancer	0.0286	0.13	CbGbCtD
Afatinib—EPHA6—Erlotinib—pancreatic cancer	0.022	0.1	CbGbCtD
Afatinib—HIPK4—Erlotinib—pancreatic cancer	0.022	0.1	CbGbCtD
Afatinib—EGFR—Erlotinib—pancreatic cancer	0.0198	0.0901	CbGbCtD
Afatinib—IRAK1—Sunitinib—pancreatic cancer	0.0164	0.0747	CbGbCtD
Afatinib—BLK—Sunitinib—pancreatic cancer	0.0145	0.0661	CbGbCtD
Afatinib—HIPK4—Sunitinib—pancreatic cancer	0.0145	0.0661	CbGbCtD
Afatinib—ABL1—Erlotinib—pancreatic cancer	0.0143	0.0652	CbGbCtD
Afatinib—EGFR—Docetaxel—pancreatic cancer	0.0131	0.0596	CbGbCtD
Afatinib—ABCG2—Tamoxifen—pancreatic cancer	0.00384	0.0175	CbGbCtD
Afatinib—ABCG2—Erlotinib—pancreatic cancer	0.00327	0.0149	CbGbCtD
Afatinib—ABCG2—Irinotecan—pancreatic cancer	0.00295	0.0134	CbGbCtD
Afatinib—ABCG2—Fluorouracil—pancreatic cancer	0.00283	0.0129	CbGbCtD
Afatinib—ABCG2—Docetaxel—pancreatic cancer	0.00216	0.00985	CbGbCtD
Afatinib—ABCG2—Sunitinib—pancreatic cancer	0.00215	0.0098	CbGbCtD
Afatinib—ABCG2—Doxorubicin—pancreatic cancer	0.00161	0.00734	CbGbCtD
Afatinib—ABCB1—Tamoxifen—pancreatic cancer	0.00139	0.00631	CbGbCtD
Afatinib—ABCB1—Gemcitabine—pancreatic cancer	0.00119	0.00544	CbGbCtD
Afatinib—ABCB1—Erlotinib—pancreatic cancer	0.00118	0.00537	CbGbCtD
Afatinib—ABCB1—Irinotecan—pancreatic cancer	0.00106	0.00485	CbGbCtD
Afatinib—ABCB1—Docetaxel—pancreatic cancer	0.00078	0.00355	CbGbCtD
Afatinib—ABCB1—Sunitinib—pancreatic cancer	0.000776	0.00353	CbGbCtD
Afatinib—ABCB1—Doxorubicin—pancreatic cancer	0.000581	0.00265	CbGbCtD
Afatinib—Vandetanib—SRC—pancreatic cancer	0.000296	0.247	CrCbGaD
Afatinib—Vandetanib—KDR—pancreatic cancer	0.000278	0.232	CrCbGaD
Afatinib—DYRK1A—Topotecan—Irinotecan—pancreatic cancer	0.00026	0.207	CbGdCrCtD
Afatinib—Vandetanib—VEGFA—pancreatic cancer	0.000236	0.197	CrCbGaD
Afatinib—ERBB2—Topotecan—Irinotecan—pancreatic cancer	0.0002	0.159	CbGdCrCtD
Afatinib—Vandetanib—EGFR—pancreatic cancer	0.000199	0.166	CrCbGaD
Afatinib—Gefitinib—EGFR—pancreatic cancer	0.000189	0.158	CrCbGaD
Afatinib—ABL1—Topotecan—Irinotecan—pancreatic cancer	0.000149	0.119	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—pancreatic cancer	6.11e-05	0.0487	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—pancreatic cancer	6.11e-05	0.0487	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—pancreatic cancer	6.11e-05	0.0487	CbGdCrCtD
Afatinib—Alopecia—Fluorouracil—pancreatic cancer	5.92e-05	0.00168	CcSEcCtD
Afatinib—Nervous system disorder—Sunitinib—pancreatic cancer	5.92e-05	0.00168	CcSEcCtD
Afatinib—Back pain—Irinotecan—pancreatic cancer	5.89e-05	0.00167	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—pancreatic cancer	5.87e-05	0.00166	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—pancreatic cancer	5.87e-05	0.00166	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—pancreatic cancer	5.87e-05	0.00166	CcSEcCtD
Afatinib—Skin disorder—Sunitinib—pancreatic cancer	5.86e-05	0.00166	CcSEcCtD
Afatinib—Muscle spasms—Irinotecan—pancreatic cancer	5.85e-05	0.00166	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—pancreatic cancer	5.8e-05	0.00164	CcSEcCtD
Afatinib—Back pain—Gemcitabine—pancreatic cancer	5.74e-05	0.00163	CcSEcCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—pancreatic cancer	5.65e-05	0.045	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—pancreatic cancer	5.65e-05	0.045	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—pancreatic cancer	5.65e-05	0.045	CbGdCrCtD
Afatinib—Sepsis—Epirubicin—pancreatic cancer	5.64e-05	0.0016	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—pancreatic cancer	5.55e-05	0.00157	CcSEcCtD
Afatinib—Body temperature increased—Erlotinib—pancreatic cancer	5.51e-05	0.00156	CcSEcCtD
Afatinib—Weight decreased—Docetaxel—pancreatic cancer	5.47e-05	0.00155	CcSEcCtD
Afatinib—Insomnia—Sunitinib—pancreatic cancer	5.46e-05	0.00155	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—pancreatic cancer	5.43e-05	0.00154	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—pancreatic cancer	5.43e-05	0.00154	CcSEcCtD
Afatinib—Pneumonia—Docetaxel—pancreatic cancer	5.42e-05	0.00154	CcSEcCtD
Afatinib—Infestation—Docetaxel—pancreatic cancer	5.39e-05	0.00153	CcSEcCtD
Afatinib—Infestation NOS—Docetaxel—pancreatic cancer	5.39e-05	0.00153	CcSEcCtD
Afatinib—Dyspnoea—Sunitinib—pancreatic cancer	5.38e-05	0.00152	CcSEcCtD
Afatinib—Cough—Irinotecan—pancreatic cancer	5.31e-05	0.00151	CcSEcCtD
Afatinib—Dyspepsia—Sunitinib—pancreatic cancer	5.31e-05	0.00151	CcSEcCtD
Afatinib—Renal failure—Docetaxel—pancreatic cancer	5.29e-05	0.0015	CcSEcCtD
Afatinib—Stomatitis—Docetaxel—pancreatic cancer	5.25e-05	0.00149	CcSEcCtD
Afatinib—Decreased appetite—Sunitinib—pancreatic cancer	5.24e-05	0.00149	CcSEcCtD
Afatinib—Conjunctivitis—Docetaxel—pancreatic cancer	5.24e-05	0.00148	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—pancreatic cancer	5.21e-05	0.00148	CcSEcCtD
Afatinib—Gastrointestinal disorder—Sunitinib—pancreatic cancer	5.21e-05	0.00148	CcSEcCtD
Afatinib—Fatigue—Sunitinib—pancreatic cancer	5.2e-05	0.00147	CcSEcCtD
Afatinib—Cough—Gemcitabine—pancreatic cancer	5.18e-05	0.00147	CcSEcCtD
Afatinib—Constipation—Sunitinib—pancreatic cancer	5.16e-05	0.00146	CcSEcCtD
Afatinib—Hepatobiliary disease—Docetaxel—pancreatic cancer	5.09e-05	0.00144	CcSEcCtD
Afatinib—Epistaxis—Docetaxel—pancreatic cancer	5.08e-05	0.00144	CcSEcCtD
Afatinib—Asthenia—Tamoxifen—pancreatic cancer	5.05e-05	0.00143	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	5.01e-05	0.00142	CcSEcCtD
Afatinib—Asthenia—Erlotinib—pancreatic cancer	5e-05	0.00142	CcSEcCtD
Afatinib—Pruritus—Tamoxifen—pancreatic cancer	4.98e-05	0.00141	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—pancreatic cancer	4.95e-05	0.0014	CcSEcCtD
Afatinib—Infection—Irinotecan—pancreatic cancer	4.94e-05	0.0014	CcSEcCtD
Afatinib—Pruritus—Erlotinib—pancreatic cancer	4.93e-05	0.0014	CcSEcCtD
Afatinib—Nervous system disorder—Irinotecan—pancreatic cancer	4.87e-05	0.00138	CcSEcCtD
Afatinib—Diarrhoea—Tamoxifen—pancreatic cancer	4.82e-05	0.00137	CcSEcCtD
Afatinib—Infection—Gemcitabine—pancreatic cancer	4.81e-05	0.00136	CcSEcCtD
Afatinib—Urinary tract disorder—Docetaxel—pancreatic cancer	4.77e-05	0.00135	CcSEcCtD
Afatinib—Body temperature increased—Sunitinib—pancreatic cancer	4.77e-05	0.00135	CcSEcCtD
Afatinib—Diarrhoea—Erlotinib—pancreatic cancer	4.77e-05	0.00135	CcSEcCtD
Afatinib—Connective tissue disorder—Docetaxel—pancreatic cancer	4.75e-05	0.00135	CcSEcCtD
Afatinib—Nervous system disorder—Gemcitabine—pancreatic cancer	4.75e-05	0.00135	CcSEcCtD
Afatinib—Urethral disorder—Docetaxel—pancreatic cancer	4.74e-05	0.00134	CcSEcCtD
Afatinib—Infection—Fluorouracil—pancreatic cancer	4.73e-05	0.00134	CcSEcCtD
Afatinib—Skin disorder—Gemcitabine—pancreatic cancer	4.7e-05	0.00133	CcSEcCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—pancreatic cancer	4.7e-05	0.0374	CbGdCrCtD
Afatinib—Nervous system disorder—Fluorouracil—pancreatic cancer	4.67e-05	0.00132	CcSEcCtD
Afatinib—Dizziness—Tamoxifen—pancreatic cancer	4.66e-05	0.00132	CcSEcCtD
Afatinib—Dizziness—Erlotinib—pancreatic cancer	4.61e-05	0.00131	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—pancreatic cancer	4.58e-05	0.0013	CcSEcCtD
Afatinib—Eye disorder—Docetaxel—pancreatic cancer	4.52e-05	0.00128	CcSEcCtD
Afatinib—Insomnia—Irinotecan—pancreatic cancer	4.49e-05	0.00127	CcSEcCtD
Afatinib—Vomiting—Tamoxifen—pancreatic cancer	4.48e-05	0.00127	CcSEcCtD
Afatinib—Rash—Tamoxifen—pancreatic cancer	4.44e-05	0.00126	CcSEcCtD
Afatinib—Dermatitis—Tamoxifen—pancreatic cancer	4.44e-05	0.00126	CcSEcCtD
Afatinib—Vomiting—Erlotinib—pancreatic cancer	4.43e-05	0.00126	CcSEcCtD
Afatinib—Dyspnoea—Irinotecan—pancreatic cancer	4.43e-05	0.00126	CcSEcCtD
Afatinib—Headache—Tamoxifen—pancreatic cancer	4.41e-05	0.00125	CcSEcCtD
Afatinib—Rash—Erlotinib—pancreatic cancer	4.39e-05	0.00125	CcSEcCtD
Afatinib—Dermatitis—Erlotinib—pancreatic cancer	4.39e-05	0.00124	CcSEcCtD
Afatinib—Dehydration—Epirubicin—pancreatic cancer	4.38e-05	0.00124	CcSEcCtD
Afatinib—Insomnia—Gemcitabine—pancreatic cancer	4.38e-05	0.00124	CcSEcCtD
Afatinib—Dyspepsia—Irinotecan—pancreatic cancer	4.37e-05	0.00124	CcSEcCtD
Afatinib—Headache—Erlotinib—pancreatic cancer	4.37e-05	0.00124	CcSEcCtD
Afatinib—Mediastinal disorder—Docetaxel—pancreatic cancer	4.36e-05	0.00124	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—pancreatic cancer	4.35e-05	0.0346	CbGdCrCtD
Afatinib—Asthenia—Sunitinib—pancreatic cancer	4.33e-05	0.00123	CcSEcCtD
Afatinib—Dry skin—Epirubicin—pancreatic cancer	4.32e-05	0.00122	CcSEcCtD
Afatinib—Decreased appetite—Irinotecan—pancreatic cancer	4.32e-05	0.00122	CcSEcCtD
Afatinib—Dyspnoea—Gemcitabine—pancreatic cancer	4.32e-05	0.00122	CcSEcCtD
Afatinib—Insomnia—Fluorouracil—pancreatic cancer	4.3e-05	0.00122	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—pancreatic cancer	4.29e-05	0.00122	CcSEcCtD
Afatinib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	4.29e-05	0.00122	CcSEcCtD
Afatinib—Fatigue—Irinotecan—pancreatic cancer	4.28e-05	0.00121	CcSEcCtD
Afatinib—Alopecia—Docetaxel—pancreatic cancer	4.27e-05	0.00121	CcSEcCtD
Afatinib—Pruritus—Sunitinib—pancreatic cancer	4.27e-05	0.00121	CcSEcCtD
Afatinib—Constipation—Irinotecan—pancreatic cancer	4.25e-05	0.0012	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	4.25e-05	0.0012	CcSEcCtD
Afatinib—Dyspnoea—Fluorouracil—pancreatic cancer	4.24e-05	0.0012	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—pancreatic cancer	4.24e-05	0.0012	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—pancreatic cancer	4.22e-05	0.00119	CcSEcCtD
Afatinib—Malnutrition—Docetaxel—pancreatic cancer	4.21e-05	0.00119	CcSEcCtD
Afatinib—Decreased appetite—Gemcitabine—pancreatic cancer	4.21e-05	0.00119	CcSEcCtD
Afatinib—Dyspepsia—Fluorouracil—pancreatic cancer	4.19e-05	0.00119	CcSEcCtD
Afatinib—Nausea—Tamoxifen—pancreatic cancer	4.18e-05	0.00119	CcSEcCtD
Afatinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	4.18e-05	0.00118	CcSEcCtD
Afatinib—Fatigue—Gemcitabine—pancreatic cancer	4.17e-05	0.00118	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	4.16e-05	0.00118	CcSEcCtD
Afatinib—Constipation—Gemcitabine—pancreatic cancer	4.14e-05	0.00117	CcSEcCtD
Afatinib—Nausea—Erlotinib—pancreatic cancer	4.14e-05	0.00117	CcSEcCtD
Afatinib—Decreased appetite—Fluorouracil—pancreatic cancer	4.14e-05	0.00117	CcSEcCtD
Afatinib—Diarrhoea—Sunitinib—pancreatic cancer	4.13e-05	0.00117	CcSEcCtD
Afatinib—Dysgeusia—Docetaxel—pancreatic cancer	4.12e-05	0.00117	CcSEcCtD
Afatinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	4.11e-05	0.00116	CcSEcCtD
Afatinib—Back pain—Docetaxel—pancreatic cancer	4.07e-05	0.00115	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—pancreatic cancer	4.06e-05	0.00115	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—pancreatic cancer	4.05e-05	0.00115	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—pancreatic cancer	4e-05	0.00113	CcSEcCtD
Afatinib—Dizziness—Sunitinib—pancreatic cancer	3.99e-05	0.00113	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—pancreatic cancer	3.97e-05	0.00113	CcSEcCtD
Afatinib—Body temperature increased—Irinotecan—pancreatic cancer	3.93e-05	0.00111	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	3.93e-05	0.00111	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—pancreatic cancer	3.9e-05	0.00111	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	3.85e-05	0.00109	CcSEcCtD
Afatinib—Vomiting—Sunitinib—pancreatic cancer	3.84e-05	0.00109	CcSEcCtD
Afatinib—Body temperature increased—Gemcitabine—pancreatic cancer	3.83e-05	0.00108	CcSEcCtD
Afatinib—Rash—Sunitinib—pancreatic cancer	3.8e-05	0.00108	CcSEcCtD
Afatinib—Dermatitis—Sunitinib—pancreatic cancer	3.8e-05	0.00108	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—pancreatic cancer	3.79e-05	0.00107	CcSEcCtD
Afatinib—Headache—Sunitinib—pancreatic cancer	3.78e-05	0.00107	CcSEcCtD
Afatinib—Body temperature increased—Fluorouracil—pancreatic cancer	3.76e-05	0.00107	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—pancreatic cancer	3.69e-05	0.00104	CcSEcCtD
Afatinib—Cough—Docetaxel—pancreatic cancer	3.67e-05	0.00104	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—pancreatic cancer	3.65e-05	0.00104	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—pancreatic cancer	3.63e-05	0.00103	CcSEcCtD
Afatinib—Infestation—Epirubicin—pancreatic cancer	3.63e-05	0.00103	CcSEcCtD
Afatinib—Nausea—Sunitinib—pancreatic cancer	3.58e-05	0.00102	CcSEcCtD
Afatinib—Renal failure—Epirubicin—pancreatic cancer	3.57e-05	0.00101	CcSEcCtD
Afatinib—Asthenia—Irinotecan—pancreatic cancer	3.57e-05	0.00101	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	3.56e-05	0.00101	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—pancreatic cancer	3.54e-05	0.001	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—pancreatic cancer	3.53e-05	0.001	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—pancreatic cancer	3.53e-05	0.001	CcSEcCtD
Afatinib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	3.51e-05	0.028	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	3.51e-05	0.028	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	3.51e-05	0.028	CbGdCrCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	3.5e-05	0.000993	CcSEcCtD
Afatinib—Asthenia—Gemcitabine—pancreatic cancer	3.47e-05	0.000984	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	3.44e-05	0.000974	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—pancreatic cancer	3.43e-05	0.000971	CcSEcCtD
Afatinib—Pruritus—Gemcitabine—pancreatic cancer	3.42e-05	0.000971	CcSEcCtD
Afatinib—Infection—Docetaxel—pancreatic cancer	3.41e-05	0.000967	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—pancreatic cancer	3.41e-05	0.000967	CcSEcCtD
Afatinib—Diarrhoea—Irinotecan—pancreatic cancer	3.4e-05	0.000964	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—pancreatic cancer	3.38e-05	0.000958	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—pancreatic cancer	3.37e-05	0.000955	CcSEcCtD
Afatinib—Pruritus—Fluorouracil—pancreatic cancer	3.37e-05	0.000954	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—pancreatic cancer	3.36e-05	0.000953	CcSEcCtD
Afatinib—Infestation—Doxorubicin—pancreatic cancer	3.36e-05	0.000953	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—pancreatic cancer	3.34e-05	0.000946	CcSEcCtD
Afatinib—Diarrhoea—Gemcitabine—pancreatic cancer	3.31e-05	0.000939	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—pancreatic cancer	3.3e-05	0.000937	CcSEcCtD
Afatinib—Dizziness—Irinotecan—pancreatic cancer	3.29e-05	0.000931	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—pancreatic cancer	3.28e-05	0.000929	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—pancreatic cancer	3.27e-05	0.000926	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—pancreatic cancer	3.27e-05	0.000926	CcSEcCtD
Afatinib—Diarrhoea—Fluorouracil—pancreatic cancer	3.26e-05	0.000923	CcSEcCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	3.25e-05	0.0259	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	3.25e-05	0.0259	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	3.25e-05	0.0259	CbGdCrCtD
Afatinib—Urinary tract disorder—Epirubicin—pancreatic cancer	3.22e-05	0.000913	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—pancreatic cancer	3.2e-05	0.000908	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—pancreatic cancer	3.2e-05	0.000906	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	3.18e-05	0.000901	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—pancreatic cancer	3.17e-05	0.000899	CcSEcCtD
Afatinib—Vomiting—Irinotecan—pancreatic cancer	3.16e-05	0.000896	CcSEcCtD
Afatinib—Dizziness—Fluorouracil—pancreatic cancer	3.15e-05	0.000892	CcSEcCtD
Afatinib—Rash—Irinotecan—pancreatic cancer	3.13e-05	0.000888	CcSEcCtD
Afatinib—Dermatitis—Irinotecan—pancreatic cancer	3.13e-05	0.000887	CcSEcCtD
Afatinib—Headache—Irinotecan—pancreatic cancer	3.11e-05	0.000882	CcSEcCtD
Afatinib—Insomnia—Docetaxel—pancreatic cancer	3.11e-05	0.000881	CcSEcCtD
Afatinib—Vomiting—Gemcitabine—pancreatic cancer	3.08e-05	0.000872	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—pancreatic cancer	3.06e-05	0.000868	CcSEcCtD
Afatinib—Rash—Gemcitabine—pancreatic cancer	3.05e-05	0.000865	CcSEcCtD
Afatinib—Dermatitis—Gemcitabine—pancreatic cancer	3.05e-05	0.000864	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—pancreatic cancer	3.05e-05	0.000864	CcSEcCtD
Afatinib—Headache—Gemcitabine—pancreatic cancer	3.03e-05	0.000859	CcSEcCtD
Afatinib—Vomiting—Fluorouracil—pancreatic cancer	3.03e-05	0.000858	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—pancreatic cancer	3.02e-05	0.000857	CcSEcCtD
Afatinib—Rash—Fluorouracil—pancreatic cancer	3e-05	0.000851	CcSEcCtD
Afatinib—Dermatitis—Fluorouracil—pancreatic cancer	3e-05	0.00085	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—pancreatic cancer	2.99e-05	0.000846	CcSEcCtD
Afatinib—Headache—Fluorouracil—pancreatic cancer	2.98e-05	0.000845	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.98e-05	0.000845	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.97e-05	0.000841	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	2.97e-05	0.00084	CcSEcCtD
Afatinib—Fatigue—Docetaxel—pancreatic cancer	2.96e-05	0.000839	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—pancreatic cancer	2.96e-05	0.000838	CcSEcCtD
Afatinib—Nausea—Irinotecan—pancreatic cancer	2.95e-05	0.000837	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—pancreatic cancer	2.94e-05	0.000833	CcSEcCtD
Afatinib—Constipation—Docetaxel—pancreatic cancer	2.94e-05	0.000833	CcSEcCtD
Afatinib—Alopecia—Epirubicin—pancreatic cancer	2.88e-05	0.000817	CcSEcCtD
Afatinib—Nausea—Gemcitabine—pancreatic cancer	2.88e-05	0.000815	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—pancreatic cancer	2.86e-05	0.00081	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—pancreatic cancer	2.84e-05	0.000805	CcSEcCtD
Afatinib—Nausea—Fluorouracil—pancreatic cancer	2.83e-05	0.000801	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—pancreatic cancer	2.82e-05	0.000799	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—pancreatic cancer	2.78e-05	0.000788	CcSEcCtD
Afatinib—Back pain—Epirubicin—pancreatic cancer	2.75e-05	0.000778	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—pancreatic cancer	2.73e-05	0.000774	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.72e-05	0.000771	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—pancreatic cancer	2.72e-05	0.00077	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—pancreatic cancer	2.67e-05	0.000756	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—pancreatic cancer	2.64e-05	0.000749	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—pancreatic cancer	2.63e-05	0.000745	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—pancreatic cancer	2.57e-05	0.000729	CcSEcCtD
Afatinib—Back pain—Doxorubicin—pancreatic cancer	2.54e-05	0.00072	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—pancreatic cancer	2.53e-05	0.000716	CcSEcCtD
Afatinib—Cough—Epirubicin—pancreatic cancer	2.48e-05	0.000702	CcSEcCtD
Afatinib—Asthenia—Docetaxel—pancreatic cancer	2.46e-05	0.000699	CcSEcCtD
Afatinib—Pruritus—Docetaxel—pancreatic cancer	2.43e-05	0.000689	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	2.4e-05	0.00068	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—pancreatic cancer	2.35e-05	0.000666	CcSEcCtD
Afatinib—Infection—Epirubicin—pancreatic cancer	2.3e-05	0.000652	CcSEcCtD
Afatinib—Cough—Doxorubicin—pancreatic cancer	2.29e-05	0.00065	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—pancreatic cancer	2.27e-05	0.000644	CcSEcCtD
Afatinib—Dizziness—Docetaxel—pancreatic cancer	2.27e-05	0.000644	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—pancreatic cancer	2.25e-05	0.000638	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	2.22e-05	0.000629	CcSEcCtD
Afatinib—Vomiting—Docetaxel—pancreatic cancer	2.18e-05	0.000619	CcSEcCtD
Afatinib—Rash—Docetaxel—pancreatic cancer	2.17e-05	0.000614	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—pancreatic cancer	2.16e-05	0.000613	CcSEcCtD
Afatinib—Headache—Docetaxel—pancreatic cancer	2.15e-05	0.00061	CcSEcCtD
Afatinib—Infection—Doxorubicin—pancreatic cancer	2.13e-05	0.000604	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—pancreatic cancer	2.1e-05	0.000596	CcSEcCtD
Afatinib—Insomnia—Epirubicin—pancreatic cancer	2.1e-05	0.000594	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—pancreatic cancer	2.08e-05	0.00059	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—pancreatic cancer	2.07e-05	0.000585	CcSEcCtD
Afatinib—Nausea—Docetaxel—pancreatic cancer	2.04e-05	0.000578	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—pancreatic cancer	2.04e-05	0.000578	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—pancreatic cancer	2.01e-05	0.000571	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	2e-05	0.000567	CcSEcCtD
Afatinib—Fatigue—Epirubicin—pancreatic cancer	2e-05	0.000566	CcSEcCtD
Afatinib—Constipation—Epirubicin—pancreatic cancer	1.98e-05	0.000562	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—pancreatic cancer	1.94e-05	0.00055	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—pancreatic cancer	1.91e-05	0.000542	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—pancreatic cancer	1.89e-05	0.000535	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—pancreatic cancer	1.86e-05	0.000528	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.85e-05	0.000525	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—pancreatic cancer	1.85e-05	0.000524	CcSEcCtD
Afatinib—Constipation—Doxorubicin—pancreatic cancer	1.83e-05	0.00052	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—pancreatic cancer	1.83e-05	0.000519	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—pancreatic cancer	1.69e-05	0.00048	CcSEcCtD
Afatinib—Asthenia—Epirubicin—pancreatic cancer	1.66e-05	0.000471	CcSEcCtD
Afatinib—Pruritus—Epirubicin—pancreatic cancer	1.64e-05	0.000465	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—pancreatic cancer	1.59e-05	0.000449	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—pancreatic cancer	1.54e-05	0.000436	CcSEcCtD
Afatinib—Dizziness—Epirubicin—pancreatic cancer	1.53e-05	0.000434	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—pancreatic cancer	1.52e-05	0.00043	CcSEcCtD
Afatinib—Vomiting—Epirubicin—pancreatic cancer	1.47e-05	0.000418	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—pancreatic cancer	1.47e-05	0.000416	CcSEcCtD
Afatinib—Rash—Epirubicin—pancreatic cancer	1.46e-05	0.000414	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—pancreatic cancer	1.46e-05	0.000414	CcSEcCtD
Afatinib—Headache—Epirubicin—pancreatic cancer	1.45e-05	0.000411	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—pancreatic cancer	1.42e-05	0.000402	CcSEcCtD
Afatinib—Nausea—Epirubicin—pancreatic cancer	1.38e-05	0.00039	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—pancreatic cancer	1.36e-05	0.000386	CcSEcCtD
Afatinib—Rash—Doxorubicin—pancreatic cancer	1.35e-05	0.000383	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—pancreatic cancer	1.35e-05	0.000383	CcSEcCtD
Afatinib—Headache—Doxorubicin—pancreatic cancer	1.34e-05	0.000381	CcSEcCtD
Afatinib—Nausea—Doxorubicin—pancreatic cancer	1.27e-05	0.000361	CcSEcCtD
Afatinib—ERBB2—Immune System—HRAS—pancreatic cancer	1.61e-06	3.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—PIK3CA—pancreatic cancer	1.6e-06	3.91e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—pancreatic cancer	1.6e-06	3.91e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—pancreatic cancer	1.6e-06	3.91e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDH1—pancreatic cancer	1.59e-06	3.89e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—pancreatic cancer	1.59e-06	3.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTEN—pancreatic cancer	1.59e-06	3.88e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A2—pancreatic cancer	1.59e-06	3.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NRAS—pancreatic cancer	1.59e-06	3.88e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—pancreatic cancer	1.58e-06	3.86e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGF—pancreatic cancer	1.58e-06	3.86e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CD—pancreatic cancer	1.58e-06	3.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—PIK3CA—pancreatic cancer	1.58e-06	3.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—pancreatic cancer	1.58e-06	3.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HES1—pancreatic cancer	1.57e-06	3.84e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—pancreatic cancer	1.57e-06	3.83e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTEN—pancreatic cancer	1.57e-06	3.83e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—pancreatic cancer	1.56e-06	3.81e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—pancreatic cancer	1.56e-06	3.81e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMAD4—pancreatic cancer	1.55e-06	3.79e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CA—pancreatic cancer	1.54e-06	3.77e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—pancreatic cancer	1.54e-06	3.75e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—pancreatic cancer	1.53e-06	3.74e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CD—pancreatic cancer	1.53e-06	3.73e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CD—pancreatic cancer	1.52e-06	3.72e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—pancreatic cancer	1.52e-06	3.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HES1—pancreatic cancer	1.52e-06	3.7e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—pancreatic cancer	1.51e-06	3.69e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—pancreatic cancer	1.51e-06	3.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CB—pancreatic cancer	1.51e-06	3.68e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—pancreatic cancer	1.51e-06	3.68e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—pancreatic cancer	1.49e-06	3.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—pancreatic cancer	1.48e-06	3.62e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SRC—pancreatic cancer	1.48e-06	3.6e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—pancreatic cancer	1.46e-06	3.57e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CD—pancreatic cancer	1.46e-06	3.56e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SRC—pancreatic cancer	1.45e-06	3.55e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—pancreatic cancer	1.45e-06	3.54e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—pancreatic cancer	1.45e-06	3.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—pancreatic cancer	1.45e-06	3.53e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—pancreatic cancer	1.44e-06	3.52e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.44e-06	3.51e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—pancreatic cancer	1.44e-06	3.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—pancreatic cancer	1.44e-06	3.51e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTNNB1—pancreatic cancer	1.43e-06	3.49e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—pancreatic cancer	1.43e-06	3.48e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—pancreatic cancer	1.42e-06	3.47e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—pancreatic cancer	1.42e-06	3.47e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—pancreatic cancer	1.42e-06	3.46e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—pancreatic cancer	1.42e-06	3.46e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CD—pancreatic cancer	1.41e-06	3.43e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—pancreatic cancer	1.4e-06	3.42e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—pancreatic cancer	1.4e-06	3.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—pancreatic cancer	1.4e-06	3.41e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—pancreatic cancer	1.39e-06	3.4e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—pancreatic cancer	1.39e-06	3.39e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—pancreatic cancer	1.38e-06	3.38e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—pancreatic cancer	1.38e-06	3.37e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—pancreatic cancer	1.38e-06	3.36e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CB—pancreatic cancer	1.38e-06	3.36e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—pancreatic cancer	1.37e-06	3.34e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—pancreatic cancer	1.35e-06	3.28e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—pancreatic cancer	1.33e-06	3.26e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—pancreatic cancer	1.33e-06	3.26e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—pancreatic cancer	1.33e-06	3.25e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CB—pancreatic cancer	1.33e-06	3.25e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—pancreatic cancer	1.33e-06	3.24e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CB—pancreatic cancer	1.33e-06	3.24e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—pancreatic cancer	1.32e-06	3.23e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—pancreatic cancer	1.32e-06	3.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HIF1A—pancreatic cancer	1.32e-06	3.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TSC2—pancreatic cancer	1.32e-06	3.21e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—pancreatic cancer	1.31e-06	3.2e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—pancreatic cancer	1.3e-06	3.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—pancreatic cancer	1.3e-06	3.17e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—pancreatic cancer	1.3e-06	3.17e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—pancreatic cancer	1.29e-06	3.16e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—SRC—pancreatic cancer	1.29e-06	3.15e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—pancreatic cancer	1.29e-06	3.15e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—pancreatic cancer	1.29e-06	3.14e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—pancreatic cancer	1.29e-06	3.14e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—pancreatic cancer	1.28e-06	3.13e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—pancreatic cancer	1.28e-06	3.12e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—pancreatic cancer	1.28e-06	3.11e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—pancreatic cancer	1.27e-06	3.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—pancreatic cancer	1.27e-06	3.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TSC2—pancreatic cancer	1.27e-06	3.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—pancreatic cancer	1.26e-06	3.08e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—pancreatic cancer	1.26e-06	3.08e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—pancreatic cancer	1.26e-06	3.08e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—pancreatic cancer	1.26e-06	3.06e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—pancreatic cancer	1.25e-06	3.06e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—pancreatic cancer	1.25e-06	3.04e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—pancreatic cancer	1.24e-06	3.03e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—pancreatic cancer	1.24e-06	3.03e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—pancreatic cancer	1.23e-06	3.01e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD44—pancreatic cancer	1.23e-06	3.01e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—pancreatic cancer	1.23e-06	2.99e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—pancreatic cancer	1.23e-06	2.99e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—pancreatic cancer	1.22e-06	2.98e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—pancreatic cancer	1.22e-06	2.98e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—pancreatic cancer	1.22e-06	2.97e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—pancreatic cancer	1.21e-06	2.96e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—pancreatic cancer	1.2e-06	2.94e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKBIA—pancreatic cancer	1.2e-06	2.93e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—pancreatic cancer	1.19e-06	2.91e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—pancreatic cancer	1.19e-06	2.9e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—pancreatic cancer	1.19e-06	2.9e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GCG—pancreatic cancer	1.18e-06	2.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—pancreatic cancer	1.18e-06	2.88e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—pancreatic cancer	1.18e-06	2.87e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—pancreatic cancer	1.18e-06	2.87e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—pancreatic cancer	1.16e-06	2.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—pancreatic cancer	1.16e-06	2.84e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—pancreatic cancer	1.16e-06	2.84e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—pancreatic cancer	1.16e-06	2.83e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKBIA—pancreatic cancer	1.16e-06	2.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—pancreatic cancer	1.15e-06	2.81e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EGF—pancreatic cancer	1.15e-06	2.8e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—pancreatic cancer	1.15e-06	2.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—pancreatic cancer	1.15e-06	2.8e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—pancreatic cancer	1.14e-06	2.78e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—pancreatic cancer	1.14e-06	2.77e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—pancreatic cancer	1.13e-06	2.76e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—pancreatic cancer	1.13e-06	2.76e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—pancreatic cancer	1.13e-06	2.75e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—pancreatic cancer	1.12e-06	2.74e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—pancreatic cancer	1.12e-06	2.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—STK11—pancreatic cancer	1.11e-06	2.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGF—pancreatic cancer	1.11e-06	2.7e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—pancreatic cancer	1.11e-06	2.7e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—pancreatic cancer	1.1e-06	2.69e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—pancreatic cancer	1.1e-06	2.68e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—pancreatic cancer	1.09e-06	2.66e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—pancreatic cancer	1.09e-06	2.65e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—pancreatic cancer	1.09e-06	2.65e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—pancreatic cancer	1.07e-06	2.61e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—pancreatic cancer	1.07e-06	2.61e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—pancreatic cancer	1.07e-06	2.6e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—pancreatic cancer	1.06e-06	2.6e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—pancreatic cancer	1.06e-06	2.6e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—pancreatic cancer	1.06e-06	2.59e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—pancreatic cancer	1.06e-06	2.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—pancreatic cancer	1.04e-06	2.54e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—pancreatic cancer	1.04e-06	2.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—pancreatic cancer	1.03e-06	2.51e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—pancreatic cancer	1.03e-06	2.51e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—pancreatic cancer	1.03e-06	2.5e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—pancreatic cancer	1.03e-06	2.5e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—pancreatic cancer	1.02e-06	2.5e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—pancreatic cancer	1.02e-06	2.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—pancreatic cancer	1.02e-06	2.49e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—pancreatic cancer	1.02e-06	2.49e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—pancreatic cancer	1e-06	2.44e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	9.95e-07	2.43e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—pancreatic cancer	9.86e-07	2.4e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—pancreatic cancer	9.85e-07	2.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—pancreatic cancer	9.83e-07	2.4e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—pancreatic cancer	9.83e-07	2.4e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—pancreatic cancer	9.83e-07	2.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—pancreatic cancer	9.81e-07	2.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—pancreatic cancer	9.57e-07	2.33e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—pancreatic cancer	9.56e-07	2.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—pancreatic cancer	9.54e-07	2.33e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—pancreatic cancer	9.48e-07	2.31e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—pancreatic cancer	9.45e-07	2.31e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—pancreatic cancer	9.36e-07	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—pancreatic cancer	9.33e-07	2.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	9.19e-07	2.24e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—pancreatic cancer	9.18e-07	2.24e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—pancreatic cancer	9.14e-07	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—pancreatic cancer	9.14e-07	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—pancreatic cancer	9.11e-07	2.22e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—pancreatic cancer	9.1e-07	2.22e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—pancreatic cancer	9.04e-07	2.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—pancreatic cancer	8.91e-07	2.17e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—pancreatic cancer	8.84e-07	2.16e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—pancreatic cancer	8.81e-07	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—pancreatic cancer	8.8e-07	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—pancreatic cancer	8.78e-07	2.14e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—pancreatic cancer	8.61e-07	2.1e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—pancreatic cancer	8.6e-07	2.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—pancreatic cancer	8.59e-07	2.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—pancreatic cancer	8.56e-07	2.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—pancreatic cancer	8.51e-07	2.08e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—pancreatic cancer	8.44e-07	2.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—pancreatic cancer	8.4e-07	2.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—pancreatic cancer	8.25e-07	2.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—pancreatic cancer	8.19e-07	2e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—pancreatic cancer	8.14e-07	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—pancreatic cancer	8.12e-07	1.98e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—pancreatic cancer	8.1e-07	1.97e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—pancreatic cancer	8.03e-07	1.96e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—pancreatic cancer	7.98e-07	1.95e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—pancreatic cancer	7.9e-07	1.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—pancreatic cancer	7.9e-07	1.93e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—pancreatic cancer	7.86e-07	1.92e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—pancreatic cancer	7.78e-07	1.9e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—pancreatic cancer	7.77e-07	1.9e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—pancreatic cancer	7.76e-07	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—pancreatic cancer	7.74e-07	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—pancreatic cancer	7.7e-07	1.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—pancreatic cancer	7.69e-07	1.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—pancreatic cancer	7.61e-07	1.86e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—pancreatic cancer	7.51e-07	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—pancreatic cancer	7.51e-07	1.83e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—pancreatic cancer	7.49e-07	1.83e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—pancreatic cancer	7.47e-07	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—pancreatic cancer	7.46e-07	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—pancreatic cancer	7.42e-07	1.81e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—pancreatic cancer	7.18e-07	1.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—pancreatic cancer	7.14e-07	1.74e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	7.02e-07	1.71e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—pancreatic cancer	6.95e-07	1.7e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—pancreatic cancer	6.92e-07	1.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—pancreatic cancer	6.89e-07	1.68e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—pancreatic cancer	6.88e-07	1.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—pancreatic cancer	6.87e-07	1.68e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—pancreatic cancer	6.86e-07	1.67e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—pancreatic cancer	6.77e-07	1.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—pancreatic cancer	6.7e-07	1.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—pancreatic cancer	6.64e-07	1.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—pancreatic cancer	6.64e-07	1.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—pancreatic cancer	6.62e-07	1.61e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—pancreatic cancer	6.61e-07	1.61e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—pancreatic cancer	6.4e-07	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—pancreatic cancer	6.38e-07	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—pancreatic cancer	6.34e-07	1.55e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	6.17e-07	1.51e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—pancreatic cancer	6.17e-07	1.5e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—pancreatic cancer	6.15e-07	1.5e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—pancreatic cancer	6.11e-07	1.49e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	6.06e-07	1.48e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—pancreatic cancer	6.03e-07	1.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—pancreatic cancer	5.91e-07	1.44e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—pancreatic cancer	5.7e-07	1.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—pancreatic cancer	5.43e-07	1.32e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	5.38e-07	1.31e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	5.33e-07	1.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—pancreatic cancer	5.25e-07	1.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—pancreatic cancer	5.23e-07	1.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—pancreatic cancer	5.06e-07	1.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—pancreatic cancer	5.02e-07	1.23e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—pancreatic cancer	4.95e-07	1.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—pancreatic cancer	4.84e-07	1.18e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—pancreatic cancer	4.65e-07	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—pancreatic cancer	4.44e-07	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—pancreatic cancer	4.28e-07	1.04e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	3.28e-07	8e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—pancreatic cancer	2.68e-07	6.53e-06	CbGpPWpGaD
